2,307 results on '"NON-muscle invasive bladder cancer"'
Search Results
2. Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-2)
- Published
- 2024
3. A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)
- Published
- 2024
4. Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
- Author
-
Mark D. Tyson II, M.D., M.P.H., Principal Investigator
- Published
- 2024
5. Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
- Author
-
Pin Down Bladder Cancer Research Foundation and Rockefeller University
- Published
- 2024
6. A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
- Author
-
Incyte Corporation
- Published
- 2024
7. Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)
- Published
- 2024
8. Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (ADVANCED-1)
- Published
- 2024
9. A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- Published
- 2024
10. A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- Published
- 2024
11. A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)
- Published
- 2024
12. Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
- Published
- 2024
13. A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer (Hydeal Cyst)
- Author
-
Fidia Farmaceutici s.p.a.
- Published
- 2024
14. A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)
- Author
-
Canadian Institutes of Health Research (CIHR)
- Published
- 2024
15. Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Author
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Published
- 2024
16. Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
- Published
- 2024
17. Precise Neoadjuvant Chemoresection of Low Grade NMIBC (POLO)
- Author
-
Spitalzentrum Biel
- Published
- 2024
18. CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO)
- Author
-
Patient-Centered Outcomes Research Institute and John Gore, Associate Professor, School of Medicine: Urology
- Published
- 2024
19. Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
- Author
-
Ding-Wei Ye, Clinical Professor
- Published
- 2024
20. Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review.
- Author
-
Melgarejo Segura, M. Teresa, Yáñez Castillo, Yaiza, Lozano Lorca, Macarena, Morales Martínez, Ana, Arrabal Polo, Miguel Ángel, and Arrabal Martín, Miguel
- Subjects
- *
NON-muscle invasive bladder cancer , *FEVER , *INTRAVESICAL administration , *MITOMYCIN C , *BCG immunotherapy , *DENTAL extraction , *UROTHELIUM - Abstract
• Hyperthermia-assisted chemotherapy offers a promising approach for NMIBC treatment. • COMBAT and BR-TRG-I show potential in reducing recurrence in NMIBC patients. • Unithermia's efficacy appears inferior to BCG in high-risk NMIBC. • Conduction hyperthermia devices present varied outcomes in NMIBC treatment. • Further research with standardized protocols is essential for conclusive results. Intravesical treatment for non-muscle invasive bladder cancer (NMIBC) aims to reduce recurrences and stop progression. Hyperthermia-enhanced chemotherapy with devices like COMBAT BRS, Unithermia, and BR-TRG-I is a promising alternative to conventional Bacillus de Calmette Guerin (BCG) therapy. To systematically review the efficacy of hyperthermia generated by conduction devices in the treatment of NMIBC. The review followed the preferred reporting items for systematic reviews and meta-analyses guidelines. A search was performed in the PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov databases. Two reviewers independently assessed the eligibility of candidate studies and abstracted data from studies that met the inclusion criteria. The primary endpoint was assessment of recurrence. Secondary objectives included evaluation of treatment progression and safety. Thirty studies meeting inclusion criteria underwent data extraction. In intermediate-risk NMIBC patients, COMBAT versus mitomycin C (MMC) in normothermia revealed no superiority in reducing recurrence or progression. High-risk NMIBC patients using COMBAT achieved similar or superior outcomes to BCG. BR-TRG-I demonstrated superior results over normothermia in intermediate- and high-risk NMIBC patients. Unithermia proved less effective than BCG in high-risk NMIBC. Progression outcomes were promising with COMBAT and BR-TRG-I, but comprehensive analysis was limited due to inconsistent assessment across studies. Adverse events were primarily mild-moderate, with some device-specific differences. Studies on conduction hyperthermia present great variability, which do not allow us to determine the superiority of 1 device over another in terms of recurrence, progression, and/or adverse effects. Further research with consistent administration protocols is crucial for definitive conclusions [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea.
- Author
-
Gang Kyu Kim, Young Heun Jo, Jongsoo Lee, Hyun Ho Han, Won Sik Ham, Won Sik Jang, and Ji Eun Heo
- Subjects
- *
NON-muscle invasive bladder cancer , *PROGRESSION-free survival , *BCG immunotherapy , *INTRAVESICAL administration , *KOREANS , *BLADDER cancer - Abstract
Purpose: In high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy post-transurethral resection of bladder tumor (TURBT). Intravesical gemcitabine, used as an alternative or second-line therapy amid BCG shortages, lacks outcome studies in the Korean population. Materials and Methods: Patients who received weekly intravesical gemcitabine for 6 weeks after TURBT from 2019 to 2022 were retrospectively investigated. Based on the American Urological Association risk classification, patients with high- or very high-risk NMIBC who refused cystectomy were included. Maintenance treatment was performed depending on their risk. Recurrence was defined as histologic confirmation on subsequent cystoscopic biopsies or TURBT. Disease free survival (DFS) was evaluated by the Kaplan-Meier method. Results: The study included 60 patients, comprising 45 high-risk (group 1) patients with a median age of 76 years and 15 very high-risk (group 2) patients with a median age of 68 years. Among them, 28 patients had previously received intravesical BCG. Over a median follow-up of 22 months, recurrence occurred in 31 patients in group 1 and 11 in group 2. The DFS rates of the highrisk group and the very high-risk group were 57.8% versus 40% at 1 year, 20.7% versus 21.3% at 2 years and 20.7% versus 21.3% at 3 years, respectively (p=0.831). Tis stage (p=0.042) and prostatic urethra invasion (p=0.028) were significant predictors of DFS. Cancer-specific mortality rates were 2.2% in group 1 and 6.7% in group 2 (p=0.441). Conclusions: Similar DFS outcome between high-risk and very high-risk patients were observed based on short-term results in Korea. This finding is crucial for clinical practice; however, studies analyzing more patients and long-term outcomes are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Pelvic organ-preserving radical cystectomy versus standard radical cystectomy in female patients diagnosed with bladder cancer.
- Author
-
Wang, Chuanlin and Zhang, Xin
- Subjects
- *
NON-muscle invasive bladder cancer , *PROPENSITY score matching , *BLADDER cancer , *CANCER patients , *WOMEN patients - Abstract
Background: Pelvic organ-preserving radical cystectomy (POPRC) has been reported to result in a better postoperative quality of life in female with bladder cancer compared to standard radical cystectomy (SRC). However, its oncological outcomes remain a concern. Patients and methods: Female patients with bladder cancer who underwent POPRC or SRC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was used to identify predictors of POPRC usage. To avoid the potential impact of baseline differences between groups on survival, a 1:2 propensity score matching (PSM) was implemented. After that, Kaplan-Meier curves and Log-rank tests were used to determine the significance of overall survival (OS) differences between patients in the SRC group and POPRC group. Finally, subgroup analysis based on predetermined indicators was performed. Results: A total of 2193 patients were included with a median follow-up of 53 months, of whom 233 (10.6%) received POPRC and 1960 (89.4%) received SRC. No definitive predictors of POPRC were identified. Before PSM, POPRC resulted in comparable OS to SRC (HR = 1.09, p = 0.309), while after PSM, POPRC was associated with significantly worse OS (HR = 1.23, p = 0.038). In subgroup analyses, POPRC led to non-inferior OS (HR = 1.18, 95%CI 0.71–1.95, p = 0.531) in patients with non-muscle invasive bladder cancer (NMIBC) and T2 patients (HR = 1.07, p = 0.669), but significantly worse OS in T3 patients (HR = 1.41, p = 0.02). Conclusion: Currently, patients undergoing POPRC have not undergone strict screening, and candidates for POPRC should have more stringent criteria in the future to achieve satisfactory oncological outcomes. However, flaws in the study make more evidence needed to support our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Establish TIIC signature score based the machine learning fusion in bladder cancer.
- Author
-
Zeng, Xiangju, Lu, Zhijie, Dai, Caixia, Su, Hao, Liu, Ziqi, and Cheng, Shunhua
- Subjects
TRANSURETHRAL resection of bladder ,NON-muscle invasive bladder cancer ,TUMOR-infiltrating immune cells ,BCG immunotherapy ,MACHINE learning ,INTRAVESICAL administration ,BLADDER cancer - Abstract
Background: Bladder cancer is a prevalent malignant tumor with high heterogeneity. Current treatments, such as transurethral resection of bladder tumor (TURBT) and intravesical Bacillus Calmette-Guérin (BCG) therapy, still have limitations, with approximately 30% of non-muscle-invasive bladder cancer (NMIBC) progressing to muscle-invasive bladder cancer (MIBC), and a substantial number of MIBC patients experiencing recurrence after surgery. Immunotherapy has shown potential benefits, but accurate prediction of its prognostic effects remains challenging. Methods: We analyzed bladder cancer RNA-seq data and clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and used various machine learning algorithms to screen for feature RNAs related to tumor-infiltrating immune cells (TIICs) from single-cell data. Based on these RNAs, we established a TIIC signature score and evaluated its relationship with overall survival (OS) and immunotherapy response in bladder cancer patients. Results: The study identified 171 TIIC-RNAs and selected 11 TIIC-RNAs with prognostic value through survival analysis. The TIIC signature score established using a machine learning fusion method was significantly associated with OS and showed good predictive performance in different datasets. Additionally, the signature score was negatively correlated with immunotherapy response, with patients with low TIIC feature scores showing better survival outcomes after immunotherapy. Further biological functional analysis revealed a close association between the TIIC signature score and immune regulation processes, cellular metabolism, and genetic variations. Conclusion: This study successfully constructed and validated an RNA signature scoring system based on tumor-infiltrating immune cell (TIIC) features, which can effectively predict OS and the effectiveness of immunotherapy in bladder cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.
- Author
-
Wen, Yuheng, Ming, Zhihao, Li, Hong, Zhu, Shuai, Cao, Jian, Ye, Mingji, Gan, Tian, She, Xiangqun, Zeng, Yong, and Xie, Yu
- Subjects
- *
NON-muscle invasive bladder cancer , *TRANSURETHRAL resection of bladder , *BIOMARKERS , *GENE expression , *BLADDER cancer - Abstract
This study aims to evaluate the prognostic utility of Activity-dependent neuroprotective protein (ADNP) expression in Circulating Tumor Cells (CTCs) inpatients with Non-muscle-invasive Bladder Cancer (NMIBC) undergoing Transurethral Resection of Bladder Tumor (TURBT). A prospective cohort of 74 bladder cancer patients and 22 non-cancer controls were enrolled. The expression of ADNP mRNA was detected by immunomagnetic beads-droplet digital PCR. The ADNP mRNA expression was evaluated in patients with high-risk NMIBC and those with indeterminate invasion depth post 2nd TURBT. Primary cultured bladder cancer cells and PBMCs from healthy donors were immunofluorescence stained. Our findings suggest that baseline ADNP mRNA level in CTCs shows potential as a prognostic marker for NMIBC with a sensitivity of 83.33% and a specificity of 73.58%. In comparison to baseline, ADNP mRNA expression increased post 2nd TURBT in 5 patients, where 2 experienced recurrence. Meanwhile, among the 12 patients with decreased levels, only one patient relapsed. A considerable limitation of this study entails the small sample size. The Immuno-magnetic beads-ddPCR technique provided a viable method for ADNP mRNA detection in CTCs from bladder cancer patients. The preoperative ADNP mRNA level in CTCs was identified as a prognostic indicator for NMIBC. Longitudinal monitoring of ADNP mRNA in CTCs of bladder cancer patients shows promise in evaluating treatment responses and predicting prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image.
- Author
-
Wang, Guang-Yue, Zhu, Jing-Fei, Wang, Qi-Chao, Qin, Jia-Xin, Wang, Xin-Lei, Liu, Xing, Liu, Xin-Yu, Chen, Jun-Zhi, Zhu, Jie-Fei, Zhuo, Shi-Chao, Wu, Di, Li, Na, Chao, Liu, Meng, Fan-Lai, Lu, Hao, Shi, Zhen-Duo, Jia, Zhi-Gang, and Han, Cong-Hui
- Subjects
- *
NON-muscle invasive bladder cancer , *CANCER relapse , *DEEP learning , *RECEIVER operating characteristic curves , *DECISION making - Abstract
We aimed to build a deep learning-based pathomics model to predict the early recurrence of non-muscle-infiltrating bladder cancer (NMIBC) in this work. A total of 147 patients from Xuzhou Central Hospital were enrolled as the training cohort, and 63 patients from Suqian Affiliated Hospital of Xuzhou Medical University were enrolled as the test cohort. Based on two consecutive phases of patch level prediction and WSI-level predictione, we built a pathomics model, with the initial model developed in the training cohort and subjected to transfer learning, and then the test cohort was validated for generalization. The features extracted from the visualization model were used for model interpretation. After migration learning, the area under the receiver operating characteristic curve for the deep learning-based pathomics model in the test cohort was 0.860 (95% CI 0.752–0.969), with good agreement between the migration training cohort and the test cohort in predicting recurrence, and the predicted values matched well with the observed values, with p values of 0.667766 and 0.140233 for the Hosmer–Lemeshow test, respectively. The good clinical application was observed using a decision curve analysis method. We developed a deep learning-based pathomics model showed promising performance in predicting recurrence within one year in NMIBC patients. Including 10 state prediction NMIBC recurrence group pathology features be visualized, which may be used to facilitate personalized management of NMIBC patients to avoid ineffective or unnecessary treatment for the benefit of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients.
- Author
-
Rahmat, Juwita N., Tham, Sin Mun, Ong, Ting Li, Lim, Yew Koon, Patwardhan, Mugdha Vijay, Nee Mani, Lata Raman, Kamaraj, Revathi, Chan, Yiong Huak, Chong, Tsung Wen, Chiong, Edmund, Esuvaranathan, Kesavan, and Mahendran, Ratha
- Subjects
- *
NON-muscle invasive bladder cancer , *BCG immunotherapy , *BLADDER cancer , *SINGLE nucleotide polymorphisms , *INTRAVESICAL administration - Abstract
Glutathione-S-transferases (GST) enzymes detoxify xenobiotics and are implicated in response to anticancer therapy. This study evaluated the association of GST theta 1 (GSTT1), GSTT2, and GSTT2B with Mycobacterium bovis Bacillus Calmette–Guérin (BCG) response in non-muscle-invasive bladder cancer treatment. In vitro assessments of GSTT2 knockout (KO) effects were performed using cell lines and dendritic cells (DCs) from GSTT2KO mice. Deletion of GSTT2B, GSTT1, and single-nucleotide polymorphisms in the promoter region of GSTT2 was analysed in patients (n = 205) and healthy controls (n = 150). Silencing GSTT2 expression in MGH cells (GSTT2BFL/FL) resulted in increased BCG survival (p < 0.05) and decreased cellular reactive oxygen species. In our population, there are 24.2% with GSTT2BDel/Del and 24.5% with GSTT2BFL/FL. With ≤ 8 instillations of BCG therapy (n = 51), 12.5% of GSTT2BDel/Del and 53.8% of GSTT2BFL/FL patients had a recurrence (p = 0.041). With ≥9 instillations (n = 153), the disease recurred in 45.5% of GSTT2BDel/Del and 50% of GSTT2BFL/FL. GSTT2FL/FL patients had an increased likelihood of recurrence post-BCG therapy (HR 5.5 [1.87–16.69] p < 0.002). DCs from GSTT2KO mice produced three-fold more IL6 than wild-type DCs, indicating a robust inflammatory response. To summarise, GSTT2BDel/Del patients respond better to less BCG therapy and could be candidates for a reduced surveillance regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Long survivors after radical cystectomy versus healthy population: propensity score matched analysis of health-related quality of life.
- Author
-
Mastroianni, Riccardo, Iannuzzi, Andrea, Ragusa, Alberto, Flammia, Rocco Simone, Tuderti, Gabriele, Anceschi, Umberto, Bove, Alfredo Maria, Brassetti, Aldo, D'Annunzio, Simone, Ferriero, Mariaconsiglia, Misuraca, Leonardo, Proietti, Flavia, Anselmi, Marianna, Guaglianone, Salvatore, Leonardo, Costantino, Papalia, Rocco, and Simone, Giuseppe
- Subjects
- *
NON-muscle invasive bladder cancer , *MINIMALLY invasive procedures , *PROPENSITY score matching , *QUALITY of life , *GENERAL practitioners , *BLADDER cancer - Abstract
Purpose: To investigate Health Related Quality of Life (HRQoL) features of long survivors after radical cystectomy (RC) compared to healthy population (HP) control. Methods: Patients with cT2-4/N0/M0 or Bacillus Calmette-Guérine (BCG) failure high-grade non-muscle-invasive bladder cancer (NMIBC) undergoing RC and ileal Orthotopic Neobladder (iON) from 2010 to 2015 were enrolled in "BCa cohort". Patients aged ≥ 18 yrs old, with no previous diagnosis of BCa or any genitourinary cancer disease were included from General Practitioner outpatients and enrolled in "HP cohort". A 1:1 propensity score matched (PSM) analysis was performed, and HRQoL outcomes were collected according to European Organization for Research and Treatment of Cancer (EORTC), and generic (QLQ-C30) questionnaires. Results: A total of 401 patients were enrolled in the study, 99 and 302 in BCa and HP cohorts, respectively. After applying 1:1 PSM analysis 67 patients were included for each group. Analysis of self-reported HRQoL outcomes described a better HRQoL in BCa cohort. Particularly, in the long run patients receiving RC and iON significantly experienced higher global health-status/QoL (p < 0.001), emotional (p = 0.003) and cognitive functioning (p < 0.001) than HP cohort, providing a significantly lower impairment in terms of fatigue (p = 0.004), pain (p = 0.004), dyspnea (p = 0.02) and insomnia (p = 0.005). Conclusions: Long survivors after RC and iON seems to have a major awareness of self-reported HRQoL compared to HP control group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer.
- Author
-
Guigui, Alexandre, Basile, Giuseppe, Zattoni, Fabio, Gallioli, Andrea, Verri, Paolo, Aumatell, Julia, Gondran-Tellier, Bastien, Lechevallier, Eric, Bastide, Cyrille, Uleri, Alessandro, Sica, Michele, Long-Depaquit, Thibaut, Dinoi, Giuseppe, Moro, Fabrizio Dal, Akiki, Akram, Toledano, Harry, Rajwa, Pawel, Montorsi, Francesco, Amparore, Daniele, and Porpiglia, Francesco
- Subjects
- *
TRANSURETHRAL resection of bladder , *NON-muscle invasive bladder cancer , *BCG immunotherapy , *LOGISTIC regression analysis , *PROGRESSION-free survival , *BLADDER cancer - Abstract
Purpose: To assess prognostic significance of residual tumor at repeat transurethral resection (reTUR) in contemporary non-muscle-invasive bladder cancer (NMIBC) patients. Methods: Patients were identified retrospectively from eight referral centers in France, Italy and Spain. The cohort included consecutive patients with high or very-high risk NMIBC who underwent reTUR and subsequent adjuvant BCG therapy. Results: A total of 440 high-risk NMIBC patients were screened, 29 (6%) were upstaged ≥ T2 at reTUR and 411 were analyzed (T1 stage: n = 275, 67%). Residual tumor was found in 191 cases (46%). In patients with T1 tumor on initial TURBT, persistent T1 tumor was found in 18% of reTUR (n = 49/275). In patients with high-grade Ta tumor on initial TURBT, T1 tumor was found in 6% of reTUR (n = 9/136). In multivariable logistic regression analysis, we found no statistical association between the use of photodynamic diagnosis (PDD, p = 0.4) or type of resection (conventional vs. en bloc, p = 0.6) and the risk of residual tumor. The estimated 5-yr recurrence and progression-free survival were 56% and 94%, respectively. Residual tumor was significantly associated with a higher risk of recurrence (p < 0.001) but not progression (p = 0.11). Only residual T1 tumor was associated with a higher risk of progression (p < 0.001) with an estimated 5-yr progression-free survival rate of 76%. Conclusions: ReTUR should remain a standard for T1 tumors, irrespective of the use of en bloc resection or PDD and could be safely omitted in high-grade Ta tumors. Persistent T1 tumor at reTUR should not exclude these patients from conservative management, and further studies are needed to explore the benefit of a third resection in this subgroup. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Novel therapies of treating non-muscle invasive bladder cancer when BCG therapy turns out to be insufficient – literature overview.
- Author
-
Kołodziej, Magdalena, Kozicz, Michał Andrzej, Saiuk, Nazarii, Marcicka, Justyna, Mądry, Wojciech, Mazurkiewicz, Aleksandra, Męczyńska, Joanna, Seredyński, Tomasz, Wojciechowska, Adriana, and Salasa, Weronika
- Subjects
NON-muscle invasive bladder cancer ,BCG immunotherapy ,ELECTROCONVULSIVE therapy - Abstract
Introduction: Bladder cancer is one of the most common cancers in the world. There are two forms of bladder cancer: non-muscle invasive bladder cancer and muscle invasive bladder cancer. A common treatment method for non- muscle invasive bladder cancer is intravesical BCG (Mycobaterium bovis) therapy after radical tumor resection. It is estimated that half of patients will have an insufficient response to BCG treatment. Patients using this type of therapy also report side effects more and more often. Aim of the study: The aim of this article is to discuss the latest discoveries in the treatment of non-muscle invasive bladder cancer when BCG therapy is insufficient. Material and Methods: The paper was created based on the PubMed and Scholar database. The literature was reviewed using the key words: „bladder cancer”; „BCG”; „treatment”; „side effects”; „novel therapies”. Results: The research shows that novel therapies are effective and safe compared to the use of BCG. In such patients, atezolizumab, metformin or intravesical magnesium sulfate infusions may be used as an alternative. An innovative solution is the use of HIVEC - heated chemotherapy administered intravesically. There are also drugs that potentiate the action of BCG, making the therapy more effective. These include: sasanlimab and rapamycin. Due to the side effects experienced by patients, the use of intravesical BCG is often replaced with intravesical infusions of chemotherapy drugs. Conclusion: The research shows that novel therapies are effective compared to the use of BCG. Unfortunately, more research is needed to standardize the treatment of non-muscle invasive bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Patient-derived bladder cancer organoids show stable transcript expression along cultivation.
- Author
-
Vollmer, Philipp, Amend, Bastian, Harland, Niklas, Stenzl, Arnulf, Tsaur, Igor, Maas, Moritz, Aicher, Wilhelm K., and Walz, Simon
- Subjects
- *
NON-muscle invasive bladder cancer , *GENE expression , *RNA analysis , *BLADDER cancer , *INDIVIDUALIZED medicine - Abstract
Introduction: Bladder cancer (BC) is a prevalent malignancy with high recurrence rates. Patient-derived bladder cancer organoids (BCO) pose as a promising approach in both, disease modeling and individualized treatment screening. The aim of this study was to investigate the transcriptomic plasticity in BCOs as a function of cultivation times to define ideal time periods for the applications envisioned. Methods: Tumor samples of three patients with pathologically confirmed non-muscle invasive and muscle-invasive bladder cancer were included in this study and expanded as BCOs. RNA expression was investigated at different time periods of cells in culture using differential gene expression for overall transcript expression and quantitative real-time PCR (qRT-PCR) for pathological relevant markers. Results: Differential gene expression of the BCO lines was investigated across passages 1–4, in passages 5–9 and above 9, respectively. Analysis of the entire transcriptome of the respective BCO lines revealed consistent profiles without significant alterations throughout the cultivation and expansion procedure. Notably, key transcripts like TP53, PIK3CA, BRCA1, among others, exhibited stable expression levels in the quantitative RNA analysis during the cultivation period. Conclusion: The robust transcriptome during BCO cultivation advocates for the use of earlier passages of BCOs in personalized medicine providing a time-efficient drug screening option to accelerate the counseling of patients' treatment options. Higher passages of BCOs still hold the potential in topics demanding for expanded cell masses such as medical device development and others. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
- Author
-
Holmberg, Lars, Skogmar, Sten, Garmo, Hans, Hagberg, Oskar, Häggström, Christel, Gårdmark, Truls, Ströck, Viveka, Aljabery, Firas, Jahnson, Staffan, Hosseini, Abolfazl, Jerlström, Tomas, Sherif, Amir, Söderkvist, Karin, Ullén, Anders, Malmström, Per‐Uno, and Liedberg, Fredrik
- Subjects
- *
BLADDER cancer , *INTRAVESICAL administration , *BCG immunotherapy , *TRANSURETHRAL resection of bladder , *NON-muscle invasive bladder cancer , *DRUGS - Abstract
Objectives: To investigate the cumulative incidence proportion of disseminated or local Bacillus Calmette‐Guérin (BCG) infections after adjuvant BCG instillations in patients with non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods: We analysed the timing and occurrence of BCG infections and absolute and relative risk in relation to patient characteristics available in the Swedish nationwide database 'BladderBaSe 2.0'. The cumulative incidence proportion of a BCG infection was indicated by a reported diagnosis of tuberculosis (TB) in the patient registry or filing a prescription for tuberculostatic drugs. Results: The cumulative incidence proportion was 1.1% at the 5‐year follow‐up in 5033 patients exposed to adjuvant BCG instillations. The incidence rate was highest during the first 2 years after start of BCG instillations. Women had a lower risk than men (hazard ratio 0.23, 95% confidence interval 0.07–0.74). Age and calendar time at diagnosis, comorbidity, tumour risk group, previous medication with corticosteroids, immunosuppressive drugs, or time between transurethral resection of the bladder tumour and commencing the adjuvant BCG instillation were not associated with risk. Conclusions: These data further supports that the overall risk of a BCG infection after BCG‐instillation treatment for NMIBC is low. The great majority of infections occur in the first 2 years, calling for an awareness of the diverse symptoms of BCG infection during this period. We provide evidence for male sex as a risk factor; however, the statistical precision is low and with a risk of selection bias, making it difficult to rule out the other suggested risk factors without further studies with different approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The SUB‐urothelial DUrvalumab InjEction‐1 (SUBDUE‐1) trial: first‐in‐human trial in patients with bladder cancer.
- Author
-
Hayne, Dickon, Ong, Katherine, Swarbrick, Nicole, McCombie, Steve P., Moe, Andrew, Hawks, Cynthia, Viswambaram, Pravin, Conduit, Ciara, Liow, Elizabeth, Spalding, Lisa, Lim, Jayne, Ferguson, Thomas, Meehan, Katie, Davis, Ian D., and Redfern, Andrew D.
- Subjects
- *
NON-muscle invasive bladder cancer , *BLADDER cancer , *CANCER patients , *BCG immunotherapy , *IMMUNOTHERAPY , *INTERSTITIAL cystitis - Abstract
Objectives: To assess the safety of sub‐urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations. Patients and Methods: The patients were chemotherapy and immunotherapy naïve (bacille Calmette‐Guérin allowed) with non‐metastatic muscle‐invasive bladder cancer or non‐muscle‐invasive bladder cancer planned for radical cystectomy (RC). The study was a Phase Ib 3 + 3 dose‐escalation design with sub‐urothelial injection of durvalumab at three pre‐determined doses (25, 75, 150 mg) diluted in 25 mL normal saline, injected at 25 locations (25 × 1 mL injections), at least 2 weeks before RC. Results: A total of 11 patients were recruited (10 male, one female). No significant changes were reported on American Urological Association Symptom Score or O'Leary Interstitial Cystitis Scale. In all, 14 adverse events (AEs) were reported (10 Grade 1, three Grade 2, one Grade 3), none considered immune‐related. No Grade 4 or 5 AEs were recorded. All the patients underwent RC. Tissue immune populations changed following durvalumab injection (P = 0.012), with a statistically significant increase in M2‐macrophage (CD163) when comparing the 25–150 mg dose (P = 0.021). Basal/mixed cancers showed a larger CD163 increase than luminal cancers (P = 0.033). Conclusion: Sub‐urothelial injection of durvalumab is feasible and safe without immune‐related AEs and shows local immunological effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. A novel grading approach predicts worse outcomes in stage pT1 non‐muscle‐invasive bladder cancer.
- Author
-
Haas, Maximilian, Engelmann, Simon U., Mayr, Roman, Gossler, Christopher, Pickl, Christoph, Kälble, Sebastian, Yang, Yushan, Otto, Wolfgang, Hartmann, Valerie, Burger, Maximilian, Hartmann, Arndt, Breyer, Johannes, and Eckstein, Markus
- Subjects
- *
BLADDER cancer , *NON-muscle invasive bladder cancer , *TRANSURETHRAL resection of bladder , *BLADDER obstruction , *CANCER patients , *PROGNOSIS , *OVERALL survival , *UROTHELIUM - Abstract
Objective: To develop a prognostically relevant scoring system for stage pT1 non‐muscle‐invasive bladder cancer (NMIBC) incorporating tumour budding, growth pattern and invasion pattern because the World Health Organisation grading system shows limited prognostic value in such patients. Patients and Methods: The tissue specimens and clinical data of 113 patients with stage pT1 NMIBC who underwent transurethral resection of bladder tumour were retrospectively investigated. Tumour budding, and growth and invasion patterns were evaluated and categorised into two grade groups (GGs). GGs and other clinical and histopathological variables were investigated regarding recurrence‐free survival (RFS), progression‐free survival (PFS), cancer‐specific survival (CSS) and overall survival (OS) using univariable and multivariable Cox regression analyses. Results: The integration of two tumour budding groups, two growth patterns, and two invasion patterns yielded an unfavourable GG (n = 28; 24.7%) that had a high impact on oncological outcomes. The unfavourable GG was identified as an independent RFS and OS predictor (P = 0.004 and P = 0.046, respectively) and linked to worse PFS (P = 0.001) and CSS (P = 0.001), irrespective of the European Association of Urology risk group. The unfavourable GG was associated with higher rates of BCG‐unresponsive tumours (P = 0.006). Study limitations include the retrospective, single‐centre design, diverse therapies and small cohort. Conclusions: We present a morphology‐based grading system for stage pT1 NMIBC that correlates with disease aggressiveness and oncological patient outcomes. It therefore identifies a highest risk group of stage pT1 NMIBC patients, who should be followed up more intensively or receive immediate radical cystectomy. The grading incorporates objective variables assessable on haematoxylin and eosin slides and immunohistochemistry, enabling an easy‐to‐use low‐cost approach that is applicable in daily routine. Further studies are needed to validate and confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review.
- Author
-
Taoka, Rikiya and Sugimoto, Mikio
- Subjects
- *
TRANSURETHRAL resection of bladder , *LITERATURE reviews , *ONCOLOGIC surgery , *CANCER invasiveness , *BLADDER cancer , *INTRAVESICAL administration , *BLADDER - Abstract
To preserve the bladder without compromising survival, further treatments need to be optimized to prevent the recurrence and progression of non‐muscle invasive bladder cancer. In clinical practice, transurethral resection of bladder tumors is essential for bladder cancer management. The primary goal of surgery is to achieve accurate pathological evaluation and complete resection of bladder cancer; high resection quality is required for the procedure. A representative surrogate indicator of the resection quality is the presence of the detrusor muscle in the resection specimen. Therefore, complete visual resection of bladder cancer with a muscle layer is crucial for decreasing the recurrence and progression rates of non‐muscle‐invasive bladder cancer. However, this procedure is complex and requires sufficient experience and knowledge to be performed thoroughly, safely, and efficiently. Surgical checklists represent an approach to filling the knowledge and experience gaps and improving the quality and safety of surgery. By checking items during transurethral resection, it is expected that the recording of risk factors related to recurrence and progression will improve, the rate of visually complete resection with muscles will increase, and the rate of intravesical recurrence will decrease. The simplicity of checklists is an additional benefit. In recent years, surgical checklists have received increasing attention in order to achieve high‐quality resections and reduce disparities between surgeons and institutions. This literature review outlines the evolving treatment strategies for patients with non‐muscle‐invasive bladder cancer, focusing on surgical checklists for the transurethral resection of bladder tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.
- Author
-
Lv, Maoxin, Shang, Shihao, Liu, Kepu, Wang, Yuliang, Xu, Peng, Song, Hao, Zhang, Jie, Sun, Zelong, Yan, Yuhao, Zhu, Zheng, Wu, Hao, and Li, Hao
- Subjects
- *
NON-muscle invasive bladder cancer , *BCG immunotherapy , *DRUG delivery systems , *MAGNETIC particles , *DRUG toxicity - Abstract
Bacillus Calmette–Guérin (BCG) immunotherapy has been a cornerstone treatment for non-muscle-invasive bladder cancer for decades and still faces challenges, such as severe immune adverse reactions, which reduce its use as a first-line treatment. This review examines BCG therapy's history, mechanisms, and current status, highlighting how nanotechnology and bioengineering are revitalizing its application. We discuss novel nanocarrier systems aimed at enhancing BCG's efficacy while mitigating specific side effects. These approaches promise improved tumor targeting, better drug loading, and an enhanced stimulation of anti-tumor immune responses. Key strategies involve using materials such as liposomes, polymers, and magnetic particles to encapsulate BCG or functional BCG cell wall components. Additionally, co-delivering BCG with chemotherapeutics enhances drug targeting and tumor-killing effects while reducing drug toxicity, with some studies even achieving synergistic effects. While most studies remain experimental, this research direction offers hope for overcoming BCG's limitations and advancing bladder cancer immunotherapy. Further elucidation of BCG's mechanisms and rigorous safety evaluations of new delivery systems will be crucial for translating these innovations into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
- Author
-
Benderska-Söder, Natalya, Ecke, Thorsten, Kleinlein, Lisa, Roghmann, Florian, Bismarck, Ekkehardt, van Rhijn, Bas W.G., Stenzl, Arnulf, Witjes, Johannes Alfred, Todenhöfer, Tilman, Hakenberg, Oliver W., Grimm, Marc Oliver, Goebell, Peter J., Burger, Maximilian, Jensen, Jorgen Bjerggaard, and Schmitz-Dräger, Bernd J.
- Subjects
- *
BLADDER cancer , *NON-muscle invasive bladder cancer , *URINE , *BLADDER obstruction , *UROTHELIUM - Abstract
• Follow-up of non-muscle-invasive bladder cancer (NMIBC) is based on cystoscopy • The relevance of urine markers in the surveillance of NMIBC is obscure. • This study intends to identify scenarios for the use of urine markers high-risk NMIBC. • The simulation suggests that marker-supported follow-up in high-risk NMIBC is safe. • Marker-supported follow-up will significantly reduce the number of cystoscopies. A plethora of urine markers for the management of patients with bladder cancer has been developed and studied in the past. However, the clinical impact of urine testing on patient management remains obscure. The goal of this manuscript is to identify scenarios for the potential use of molecular urine markers in the follow-up of patients with high-risk non-muscle-invasive BC (NMIBC) and estimate potential risks and benefits. Information on the course of disease of patients with high-risk NMIBC and performance data of a point-of-care test (UBC rapid™), an MCM-5 directed ELISA (ADXBLADDER™), and 2 additional novel assays targeting alterations of mRNA expression and DNA methylation (Xpert bladder cancer monitor™, Epicheck™) were retrieved from high-quality trials and/or meta-analyses. In addition, the sensitivity of white light cystoscopy (WLC) and the impact of a urine marker result on the performance of WLC were estimated based on fluorescence cystoscopy data and information from the CeFub trial. This information was applied to different scenarios in patient follow-up and sensitivity, estimated number of cystoscopies, and the numbers needed to diagnose were calculated. The sensitivity of guideline-based regular follow-up (SOC) at 1 year was calculated at 96%. For different marker-supported strategies sensitivities ranging from 77% to 97.9% were estimated. Calculations suggest that several strategies are effective for the SOC. While for the SOC 24.6 WLCs were required to diagnose 1 tumor recurrence (NND), this NND dropped below 5 in some marker-supported strategies. Based on the results of this simulation, a marker-supported follow-up of patients with HR NMIBC is safe and offers the option to significantly reduce the number of WLCs. Further research focusing on prospective randomized trials is needed to finally find a way to implement urine markers into clinical decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
- Author
-
Lotan, Yair, Agarwal, Piyush, Black, Peter, Dickstein, Rian, Kamat, Ashish M., Lee, Byron, Narayan, Vikram M., Porten, Sima, Psutka, Sarah P., Smith, Armine K., Svatek, Robert S., Williams, Stephen B., and Woldu, Solomon
- Subjects
- *
BLADDER cancer , *NON-muscle invasive bladder cancer , *CLINICAL trials , *BCG immunotherapy , *BLADDER obstruction , *URETHRA , *STANDARDIZATION - Abstract
• A standard approach to evaluation of patients within the context of clinical trials is necessary to accurately assess the efficacy of novel agents. • During surveillance of patients on clinical trial, urologists will follow the AUA guideline recommendations. • During the surveillance period, urologists should use the same cystoscopic imaging modality throughout the trial. • The timing of mandatory biopsies will occur at a prespecified time and will be consistent across trials for patients with BCG-unresponsive disease. • The recommended time for mandatory biopsies will be 12 months with a minimum of 4 cores from the bladder in addition to prostatic urethra in men. There are multiple ongoing and planned clinical trials that are evaluating novel therapies to treat patients with BCG-unresponsive high grade nonmuscle invasive bladder cancer (NMIBC). Importantly, there is considerable variation in surveillance strategies between these clinical trials, specifically with regards to the use of advanced imaging, enhanced cystoscopy, and mandatory biopsies, which could impact landmark efficacy assessments of investigational agents. To present guideline recommendations for the standardization of cystoscopic evaluation, surveillance, and efficacy assessments for patients with BCG-unresponsive NMIBC participating in clinical trials. On September 29, 2023 at the annual meeting of the International Bladder Cancer Network, a breakout session was convened, during which representatives from various disciplines discussed potential guidance statements with opportunity for discussion and comment. A set of statements regarding use of white light and enhanced cystoscopy were developed to help guide a pragmatic approach to surveillance and efficacy assessments of patients in clinical trials. The use of "for cause" and "mandatory" biopsies was also addressed. A standard approach to evaluation of patients within the context of clinical trials is necessary to accurately assess the efficacy of novel agents, especially within single arm trials that lack an appropriate comparator. Additionally, the utilization and timing of mandatory biopsies is critical, as these biopsies may impact both disease evaluations and the determination of duration of response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial.
- Author
-
Wong, Chris Ho-Ming, Lim, Joycelyn Yung-Yung, Ko, Ivan Ching-Ho, Leung, David Ka-Wai, Yuen, Steffi Kar-Kei, Yip, Siu-Ying, Ng, Chi-Fai, Teoh, Jeremy Yuen-Chun, and Chan, Eddie Shu-Yin
- Subjects
- *
TRANSURETHRAL resection of bladder , *NON-muscle invasive bladder cancer , *CLINICAL trials , *CANCER invasiveness , *PROGRESSION-free survival - Abstract
Introduction: Previously, in a randomised trial we demonstrated bipolar transurethral resection of bladder tumor (TURBT) could achieve a higher detrusor sampling rate than monopolar TURBT. We hereby report the long-term oncological outcomes following study intervention. Methods: This is a post-hoc analysis of a randomized phase III trial comparing monopolar and bipolar TURBT. Only patients with pathology of non-muscle invasive bladder cancer (NMIBC) were included in the analysis. Per-patient analysis was performed. Primary outcome was recurrence-free survival (RFS). Secondary outcomes included progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). Results: From the initial trial, 160 cases were randomised to receive monopolar or bipolar TURBT. 24 cases of non-urothelial carcinoma, 22 cases of muscle-invasive bladder cancer, and 9 cases of recurrences were excluded. A total of 97 patients were included in the analysis, with 46 in the monopolar and 51 in the bipolar group. The median follow-up was 97.1 months. Loss-to-follow-up rate was 7.2%. Regarding the primary outcome of RFS, there was no significant difference (HR = 0.731; 95%CI = 0.433–1.236; P = 0.242) between the two groups. PFS (HR = 1.014; 95%CI = 0.511–2.012; P = 0.969), CSS (HR = 0.718; 95%CI = 0.219–2.352; P = 0.584) and OS (HR = 1.135; 95%CI = 0.564–2.283; P = 0.722) were also similar between the two groups. Multifocal tumours were the only factor that was associated with worse RFS. Conclusion: Despite the superiority in detrusor sampling rate, bipolar TURBT was unable to confer long-term oncological benefits over monopolar TURBT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.
- Author
-
Arita, Yuki, Woo, Sungmin, Kwee, Thomas C., Shigeta, Keisuke, Ueda, Ryo, Nalavenkata, Sunny, Edo, Hiromi, Miyai, Kosuke, Das, Jeeban, Andrieu, Pamela I. Causa, and Vargas, Hebert Alberto
- Subjects
- *
DIFFUSION magnetic resonance imaging , *NON-muscle invasive bladder cancer , *TRANSURETHRAL resection of bladder , *MAGNETIC resonance imaging , *BLADDER - Abstract
Bladder cancer (BC), predominantly comprising urothelial carcinomas (UCs), ranks as the tenth most common cancer worldwide. UCs with variant histology (variant UC), including squamous differentiation, glandular differentiation, plasmacytoid variant, micropapillary variant, sarcomatoid variant, and nested variant, accounting for 5–10% of cases, exhibit more aggressive and advanced tumor characteristics compared to pure UC. The Vesical Imaging-Reporting and Data System (VI-RADS), established in 2018, provides guidelines for the preoperative evaluation of muscle-invasive bladder cancer (MIBC) using multiparametric magnetic resonance imaging (mpMRI). This technique integrates T2-weighted imaging (T2WI), dynamic contrast-enhanced (DCE)-MRI, and diffusion-weighted imaging (DWI) to distinguish MIBC from non-muscle-invasive bladder cancer (NMIBC). VI-RADS has demonstrated high diagnostic performance in differentiating these two categories for pure UC. However, its accuracy in detecting muscle invasion in variant UCs is currently under investigation. These variant UCs are associated with a higher likelihood of disease recurrence and require precise preoperative assessment and immediate surgical intervention. This review highlights the potential value of mpMRI for different variant UCs and explores the clinical implications and prospects of VI-RADS in managing these patients, emphasizing the need for careful interpretation of mpMRI examinations including DCE-MRI, particularly given the heterogeneity and aggressive nature of variant UCs. Additionally, the review addresses the fundamental MRI reading procedures, discusses potential causes of diagnostic errors, and considers future directions in the use of artificial intelligence and radiomics to further optimize the bladder MRI protocol. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. A monoclonal antibody that recognizes a unique 13-residue epitope in the cytoplasmic tail of HLA-E.
- Author
-
Verhaar, Elisha R., Gan, Jin, Buhl, Susan, Li, Ziao, Horowitz, Amir, and Ploegh, Hidde L.
- Subjects
- *
MONOCLONAL antibodies , *STREPTAVIDIN , *MEMBRANE glycoproteins , *NON-muscle invasive bladder cancer - Abstract
The Class I MHC molecule (MHC-I) HLA-E presents peptides that are derived from the signal sequences, either those of other MHC-I products, or of viral type I membrane glycoproteins. Monoclonal antibodies with proven specificity for HLA-E, and with no cross-reactions with other MHC-I products, have yet to be described. To obtain anti-HLA-E-specific antibodies suitable for a range of applications, we generated monoclonal antibodies against a unique feature of HLA-E: its cytoplasmic tail. We created an immunogen by performing an enzymatically catalyzed transpeptidation reaction to obtain a fusion of the cytoplasmic tail of HLA-E with a nanobody that recognizes murine Class II MHC (MHC-II) products. We obtained a mouse monoclonal antibody that recognizes a 13-residue stretch in the HLA-E cytoplasmic tail. We cloned the genes that encode this antibody in expression vectors to place an LPETG sortase recognition motif at the C-terminus of the heavy and light chains. This arrangement allows the site-specific installation of fluorophores or biotin at these C-termini. The resulting immunoglobulin preparations, labeled with 4 equivalents of a fluorescent or biotinylated payload of choice, can then be used for direct immunofluorescence or detection of the tag by fluorescence or by streptavidin-based methods. We also show that the 13-residue sequence can serve as an epitope tag, independent of the site of its placement within a protein's sequence. The antibody can be used diagnostically to stain for HLA-E on patient tumor samples, it can be used as an antibody-epitope tag for extracellular proteins, and it enables research into the unique role of the cytoplasmic tail of HLA-E. • Mouse monoclonal antibody recognizes 13-residue stretch in the HLA-E cytoplasmic tail. • mAb can be modified directly with fluorophores or biotin with sortase. • mAb stains HLA-E on tumor samples with high affinity and specificity. • mAb recognizes HLA-E in flow cytometry, immunoblot, IP, IHC, and IF. • mAb can be used as antibody-epitope tag for extracellular proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Evaluation of androgen receptor and androgen receptor splice-variant 7 in bladder cancer; a novel approach into an ancient topic.
- Author
-
Sarıkaya, Ege Alper, Korhan, Peyda, Incir, Canet, Yıldız, Alperen H., Deger, Dogan M., Özer, Selçuk M., Tuncok, Yesim, Ergor, Gul, Islakoğlu, Yasemin Ö., Sen, Volkan, Bozkurt, Ozan, Atabey, Neşe, and Esen, Adil A.
- Subjects
- *
NON-muscle invasive bladder cancer , *ANDROGEN receptors , *BLADDER cancer , *WESTERN immunoblotting , *CANCER patients - Abstract
Purpose: The contribution of androgen receptors (AR) on bladder cancer has been demonstrated in pre-clinical studies, however in clinical studies, only the canonical AR (AR-FL) protein was measured by immunohistochemistry and conflicting results were obtained. To get better insight into the alterations of AR signalling, we used western blotting (WB) method and simultaneously measured both mRNA and protein levels of AR-FL and AR-V7. Methods: 23 naive non-muscle invasive bladder cancer patients and 12 healthy individuals were included. AR-FL protein, AR-FL mRNA, AR-V7 protein and AR-V7 mRNA levels were quantitatively measured by WB and qRT-PCR. Results: While AR-FL protein and AR-V7 mRNA were significantly higher in bladder cancer, AR-FL mRNA and AR-V7 protein were lower. AR-V7 mRNA level was higher in patients with tumour size over 3 cm and AR-FL protein was higher in single tumours (p < 0,005). The small sampling size and the inclusion of only male participants were the main limitations. Conclusions: The increase of AR-FL protein in bladder cancer supports the contribution of the AR pathway in bladder cancer. The presence of high AR-FL protein despite low mRNA levels may be due to a disruption in post-transcriptional regulatory mechanisms. AR-V7 was demonstrated for the first time in bladder tissue and found significantly different in bladder cancer tissues. Our study reached new and valuable findings and will shed light on the studies that aim to clarify the role of the AR pathway in bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. A novel laser resection approach: efficacy of rotatable bi-channel en bloc resection of bladder tumor in a pilot in-vivo study.
- Author
-
Yao, Qiu, Niu, Hui, Yang, Xibin, Jiang, Huizhong, Zhou, Yanling, Shekhawat, Abhay Singh, and Xue, Boxin
- Subjects
- *
LASER surgery , *IN vivo studies , *BLADDER cancer , *PILOT projects , *NON-muscle invasive bladder cancer , *FORCEPS ,TUMOR surgery - Abstract
En bloc resection of bladder tumor (ERBT) involves removing bladder tumors and their base. Laser resection has been used to reduce complications including bleeding and obturator nerve reflex (ONR). We developed a novel approach (rotatable bi-channel en bloc resection of bladder tumor (RBC-ERBT)) and assessed its efficacy in a pilot in-vivo study to enhance laser ERBT's applicability in challenging bladder regions. In the laser RBC-ERBT procedure, lesions were excised by inserting a holmium laser through the rotating external working channel, while forceps were inserted through the internal working channel provided traction on the tissue. Fifteen laser RBC-ERBT procedures were performed in five different bladder areas of three live pigs. The technical success rate (TSR), procedure time, lesion size, occurrence of complications (bleeding, perforation, ONR), and detrusor muscle (DM) presence rate and DM thickness were evaluated. All 15 procedures were performed with a 100% TSR. The resections were successful in all bladder regions (posterior, left, right and anterior walls and dome). Median procedure time was 20 min. The resected specimen size was 10 mm × 7 mm to 17 mm × 13 mm. Mild bleeding occurred in two procedures (13.3%) but was effectively managed. No incidents of ONR or perforation were observed. Histological examination confirmed presence of DM in all specimens with a median DM thickness of 1.26 mm. Our pilot in-vivo study suggested the feasibility and effectiveness of laser RBC-ERBT for bladder tumors in various locations. This technique offers effective traction, improved visualization, and enhanced laser accessibility. Further studies are required to validate its effectiveness in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer.
- Author
-
Ye, Junjiang, Tang, Cai, Wu, Ruicheng, Tang, Yin, Yin, Hesheng, Bai, Yunjin, and Han, Ping
- Subjects
- *
NON-muscle invasive bladder cancer , *BCG immunotherapy , *TRANSURETHRAL resection of bladder , *PROGNOSIS , *RECEIVER operating characteristic curves , *UROTHELIUM - Abstract
The aim of this study was to investigate the prognostic role of blood-based nutritional biomarkers, including red blood cell (RBC count), hemoglobin (Hb), total protein (TP), albumin, the serum albumin to globulin ratio (AGR) and the prognostic nutritional index (PNI) in patients who underwent intravesical treatment for non-muscle invasive bladder cancer (NMIBC). A total of 501 NMIBC patients who received intravesical Bacillus Calmette-Guerin (BCG) treatment following transurethral resection of bladder tumor (TURBT) were included. The optimal cutoff values for these nutrition-based indicators were determined using receiver operating characteristic curve analysis. We observed a significantly higher recurrence-free survival (RFS) rate in patients with elevated levels of RBC count, Hb, TP, and albumin. Cox univariate and multivariate Cox regression analyses demonstrated that serum albumin (P = 0.002, HR = 0.51, 95%CI: 0.33–0.78), RBC count (P = 0.002, HR = 0.50, 95%CI: 0.32–0.77), TP (P = 0.028, HR = 0.62, 95%CI: 0.41–0.95), Hb (P = 0.004, HR = 0.53, 95%CI: 0.33–0.84), AGR (P = 0.003, HR = 0.46, 95%CI: 0.27–0.76) and PNI (P = 0.019, HR = 0.56, 95%CI: 0.35–0.91) were significant independent factors predicting RFS. These cost-effective and convenient blood-based nutritional biomarkers have the potential to serve as valuable prognostic indicators for predicting recurrence in NMIBC patients undergoing BCG-immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. The roles of FGFR3 and c-MYC in urothelial bladder cancer.
- Author
-
Bogale, Dereje E.
- Subjects
BLADDER cancer ,NON-muscle invasive bladder cancer ,TRANSITIONAL cell carcinoma ,FIBROBLAST growth factor receptors - Abstract
Bladder cancer is one of the most frequently occurring cancers worldwide. At diagnosis, 75% of urothelial bladder cancer cases have non-muscle invasive bladder cancer while 25% have muscle invasive or metastatic disease. Aberrantly activated fibroblast growth factor receptor (FGFR)-3 has been implicated in the pathogenesis of bladder cancer. Activating mutations of FGFR3 are observed in around 70% of NMIBC cases and ~ 15% of MIBCs. Activated FGFR3 leads to ligand-independent receptor dimerization and activation of downstream signaling pathways that promote cell proliferation and survival. FGFR3 is an important therapeutic target in bladder cancer, and clinical studies have shown the benefit of FGFR inhibitors in a subset of bladder cancer patients. c-MYC is a well-known major driver of carcinogenesis and is one of the most commonly deregulated oncogenes identified in human cancers. Studies have shown that the antitumor effects of FGFR inhibition in FGFR3 dependent bladder cancer cells and other FGFR dependent cancers may be mediated through c-MYC, a key downstream effector of activated FGFR that is involved tumorigenesis. This review will summarize the current general understanding of FGFR signaling and MYC alterations in cancer, and the role of FGFR3 and MYC dysregulation in the pathogenesis of urothelial bladder cancer with the possible therapeutic implications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?
- Author
-
Passarelli, Rachel and Packiam, Vignesh T.
- Subjects
- *
NON-muscle invasive bladder cancer , *BCG immunotherapy , *INTRAVENOUS therapy , *ENDOSCOPIC surgery , *COMBINATION drug therapy - Abstract
Non-muscle-invasive bladder cancer (NMIBC) encompasses approximately three-quarters of all bladder cancer (BC) diagnoses. Intravesical Bacillus Calmette-Guerin (BCG) has been the long-standing gold standard treatment for patients following endoscopic resection. However, despite reasonable efficacy, recurrence rates are still suboptimal, and this, combined with treatment tolerability and BCG shortages, has prompted an investigation into alternative treatment modalities. Advances in this landscape have been predominantly for patients with BCG-unresponsive disease, and there are currently four FDA-approved treatments for these patients. More recently, trials have emerged looking for alternatives to BCG for patients who are treatment-naïve. We performed a literature search via PubMed to find recent publications on alternatives to BCG, as well as a search on clinicaltrials.gov and recent conference presentations for ongoing clinical trials. Studies have shown that combination intravesical chemotherapy, combination intravesical therapy with BCG, and combination intravenous therapy with BCG preliminarily have good efficacy and safety profiles in this disease space. Ongoing trials are underway, and we anticipate as these studies mature, there will be a shift in NMIBC treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
- Author
-
Mohamed, Abdikarim Hussein, Mohamed, Khaled Ali, Kayacan, Ertan, Nur, Yassin, and Nur-amin, Mohamed Abdikarim
- Subjects
- *
NON-muscle invasive bladder cancer , *OVERALL survival , *SURVIVAL rate , *ONCOLOGY nursing , *KIDNEY pelvis , *UROTHELIUM , *TRANSITIONAL cell carcinoma - Abstract
Background: A few studies regarding the epidemiology and risk factors of Non-muscle Invasive Bladder Cancer (NMIBC) are reported from Sub-Saharan African countries (SSA), including Somalia, and the African literature is scant on the management of NMIBC. The present study aims to evaluate the clinical-histopathological characteristics and factors associated with the survival rate of patients with NMIBC. Method: This six-year cohort study included 196 patients with NMIBC. It reviewed the clinical and histopathological characteristics and factors predicting cancer-specific survival for these patients. Results: The mean patient age was 59.01 ± 11.50 years, with a male-to-female ratio of 2.8:1. Urothelial carcinoma (UC) constituted the most common pathological type, accounting for 90.8%; Ta LG and T1HG were the most common histopathological tumour stage and grade (n = 90, 45.9%, vs. n = 56, 28.6%), respectively. The mean tumour size was 4.72 ± 2.81 cm. The cancer-specific mortality(CSM) was 13.3%. Age [2.252(2.310–2.943], p < 0.001], Gender [1.031(0.981-1.1.242),p < 0.001], tumour stage and grade [4.902(3.607–5.614),p < 0.001], tumour location [1.135(0.806–1.172),p < 0.001], number [0.510(0.410–0.920),p = 0.03], tumour size [1.523(0.936–1.541),p < 0.001], use of intravesical chemotherapy or BCG [2.810(1.972–4.381),p < 0.001], preoperative hydronephrosis grade [1.517(1.172–2.154),p < 0.001], and follow-up compliance [3.376(2.633–5.018),p < 0.001] were all associated with CSM. The 5-year overall survival was 57.1%, and cardiovascular diseases were the leading cause of mortality (n = 34), followed by diabetes (n = 28). Conclusion: Our study findings revealed that UC constituted the most common pathological subtype, though less than forty per cent of our patients receive intravesical adjuvant therapies, which are crucial to minimizing disease morbidity and mortality. Initiatives improving uro-oncological care, including subspecialty training in oncology and essential cancer therapies, better access to urology services, and cancer screening programs, are much needed for optimal management plans and care in the country. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity.
- Author
-
Atallah, Aline, Grossman, Arielle, Nauman, Richard W., Paré, Jean‐François, Khan, Adam, Siemens, D. Robert, Cotechini, Tiziana, and Graham, Charles H.
- Subjects
BLADDER cancer ,NON-muscle invasive bladder cancer ,MYELOID-derived suppressor cells ,IMMUNOLOGIC memory ,CYTOTOXIC T cells ,BACILLUS (Bacteria) - Abstract
Treatment for higher‐risk non‐muscle invasive bladder cancer (NMIBC) involves intravesical immunotherapy with Bacillus Calmette Guérin (BCG); however, disease recurrence and progression occur frequently. Systemic immunity is critical for successful cancer immunotherapy; thus, recurrence of NMIBC may be due to suboptimal systemic activation of anti‐tumor immunity after local immunotherapy. We previously reported that systemically acquired trained immunity (a form of innate immune memory) in circulating monocytes is associated with increased time‐to‐recurrence in patients with NMIBC treated with BCG. Herein, we used a mouse model of NMIBC to compare the effects of intravesical versus intravenous (systemic) BCG immunotherapy on the local and peripheral immune microenvironments. We also assessed whether BCG‐induced trained immunity modulates anti‐tumor immune responses. Compared with intravesical BCG, which led to a tumor‐promoting immune microenvironment, intravenous BCG resulted in an anti‐tumoral bladder microenvironment characterized by increased proportions of cytotoxic T lymphocytes (CTLs), and decreased proportions of myeloid‐derived suppressor cells. Polarization toward anti‐tumoral immunity occurred in draining lymph nodes, spleen, and bone marrow following intravenous versus intravesical BCG treatment. Pre‐treatment with intravesical BCG was associated with increased rate of tumor growth compared with intravenous BCG pre‐treatment. Trained immunity contributed to remodeling of the tumor immune microenvironment, as co‐instillation of BCG‐trained macrophages with ovalbumin‐expressing bladder tumor cells increased the proportion of tumor‐specific CTLs. Furthermore, BCG‐trained dendritic cells exhibited enhanced antigen uptake and presentation and promoted CTL proliferation. Our data support the concept that systemic immune activation promotes anti‐tumor responses, and that BCG‐induced trained immunity is important in driving anti‐tumor adaptive immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study.
- Author
-
Wu, Peng, Zhang, Wei, Hu, Wei, Cao, Yitong, Wang, Jia, and Yu, Lei
- Subjects
BLADDER cancer ,NON-muscle invasive bladder cancer ,UROTHELIUM ,TRANSURETHRAL resection of bladder ,IMMUNE checkpoint inhibitors ,INTRAVESICAL administration ,CANCER chemotherapy - Abstract
Background: Despite adequate transurethral resection of the bladder tumor (TURBT) followed by intravesical bacillus-calmette guérin (BCG), high-risk non-muscle-invasive bladder cancer (HR-NMIBC) is associated with high rates of recurrence and progression. Immune checkpoint inhibitors can improve antitumor activity in bladder cancer, but relevant evidence in HR-NMIBC is limited. Thus, we evaluated the efficacy and safety of the tislelizumab-based combination regimen in HR-NMIBC. Methods: A retrospective study included 21 patients diagnosed with HR-NMIBC between July 2020 and September 2022. All patients underwent TURBT followed by combination regimens of tislelizumab plus BCG with or without gemcitabine/cisplatin (GC) chemotherapy. Clinical Data on demographics and characteristics, treatment information, outcomes, and safety were collected and analyzed. Results: Among the 21 patients with HR-NMIBC, the median age was 63 years (range 39–85), with the majority of patients with stage T1 (16/21, 76.19%). The median treatment of tislelizumab was 5 cycles (range 1–12) and the median number of BCG instillations was 12 times (range 2–19). Of the 21 patients, 15 (71.43%) received combination chemotherapy with GC, with a median treatment of 2 cycles (range 0–7); others did not. Overall, after the median follow-up of 25 months (range 7–31), the estimated 2-year bladder recurrence-free survival rate was 78.64% (95% confidence intervals [CIs], 50.79–91.83%), 2-year cystectomy-free survival rate was 83.00% (95% CI 53.53–94.59%), and 2-year disease-free survival rate was 73.39% (95% CI 46.14–88.36%). Sixteen stage T1 patients achieved a distant metastasis-free survival rate of 95.45% (95% CI 71.87–99.34%) at 2 years. Fourteen (66.67%) patients experienced at least one treatment related-AEs (TRAEs), with 9.52% (2/21) of grade 3–4. Grade ≥ 3 TRAEs were hypophysitis (1/21, 4.76%) and myasthenia (1/21, 4.76%). No treatment-related deaths were observed. Conclusions: The study demonstrated promising clinical benefits and a manageable safety profile of tislelizumab-based combination regimen as a bladder-sparing treatment of HR-NMIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Nogapendekin alfa Inbakicept: First Approval.
- Author
-
Keam, Susan J.
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *NON-muscle invasive bladder cancer , *HEMATOLOGIC malignancies , *IMMUNOTHERAPY , *BCG vaccines , *HIV infections , *DRUG approval , *PROGRESSION-free survival , *INTERLEUKINS , *CARCINOMA in situ , *OVERALL survival ,BLADDER tumors - Abstract
Nogapendekin alfa inbakicept (ANKTIVA®; nogapendekin alfa inbakicept-pmln) is a recombinant interleukin-15 (IL-15) superagonist protein complex being developed by Altor BioScience, LLC, an indirect wholly owned subsidiary of ImmunityBio, Inc., for the treatment of solid and haematological cancers and HIV infection. In April 2024, nogapendekin alfa inbakicept was approved for use with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours in the USA. This article summarizes the milestones in the development of nogapendekin alfa inbakicept leading to this first approval for the treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer.
- Author
-
Bakula, Mirko, Hudolin, Tvrtko, Knezevic, Nikola, Zimak, Zoran, Andelic, Jerko, Juric, Ilija, Gamulin, Marija, Gnjidic, Milena, and Kastelan, Zeljko
- Subjects
- *
NON-muscle invasive bladder cancer , *INTRAVESICAL administration , *BCG immunotherapy , *CARCINOMA in situ , *PROGRESSION-free survival - Abstract
Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration of gemcitabine and docetaxel (Gem/Doce) as a first-line treatment for BCG-naïve patients with high-risk NMIBC (HR NMIBC). From October 2019 until April 2022, we enrolled 52 patients and followed the treatment protocol set forth by the University of Iowa. Follow-up assessments were conducted every 3 months. In this cohort, 25 (48.1%) patients were diagnosed with high-grade T1 (T1HG) bladder cancer, 10 (19.2%) patients had carcinoma in situ (CIS), and 17 (32.7%) patients had a combination of T1HG+CIS. The median time to first recurrence in the T1HG, CIS, and T1HG+CIS groups was 11, 10.5, and 8.8 months, respectively. The recurrence-free survival was 98.1%, 94.2%, and 80.8% at 6, 9, and 12 months, respectively. The rate of progression-free survival was 100%, 98.1%, and 92.3% at 6, 9, and 12 months, respectively. We demonstrated the safety and efficacy of Gem/Doce therapy in BCG-naïve patients with HR NMIBC during a one-year follow-up. Further research with extended follow-ups, as well as direct comparisons of Gem/Doce with other anticancer agents, is essential. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.